What is BEAM's current stock price?

BEAM (Beam Therapeutics Inc.) is currently trading at $28.64 with a market cap of $2.95B.

What sector is Beam Therapeutics Inc. in?

Beam Therapeutics Inc. (BEAM) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BEAM a good stock to buy?

Analysts have a Buy consensus on BEAM with a price target of $48.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BEAM Beam Therapeutics Inc.

Healthcare

$28.64+3.51%ClosedMarket Cap: $2.95B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.54

P/S

17.96

EV/EBITDA

-46.33

DCF Value

$-35.65

FCF Yield

-13.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

-32.4%

Operating Margin

-226.6%

Net Margin

-39.7%

ROE

-5.9%

ROA

-4.4%

ROIC

-26.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$31.7M	$-94.3M	$—
Q4 null	$114.1M	$244.3M	$—
FY null	$139.7M	$-80.0M	$—
Q3 null	$9.7M	$-112.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$48.00

Target (Median)

$40.00

Target Range

$26.00 - $80.00

1 Strong Buy14 Buy2 Hold0 Sell0 Strong Sell

BernsteinOutperform

2026-05-13

CitigroupBuy

2026-03-26

WedbushOutperform

2026-02-25

RBC CapitalSector Perform

2026-02-25

BernsteinOutperform

2026-01-21

Trading Activity

Insider Trades

View All

Simon Amyofficer: Chief Medical Officer

SellMon Apr 06

Evans John M.director, officer: CEO

SellMon Apr 06

Ciaramella Giuseppeofficer: President

SellMon Apr 06

Cavanagh Bethany Jofficer: SVP, Finance and Treasurer

SellMon Apr 06

Bellon Christineofficer: Chief Legal Officer

SellMon Apr 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.26

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Peers